These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 25403210)
21. POINT: HER2-Targeted Combinations in Advanced HER2-Positive Breast Cancer. Goel S; Winer EP Oncology (Williston Park); 2015 Nov; 29(11):797-8, 802. PubMed ID: 26573058 [No Abstract] [Full Text] [Related]
22. Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. Perez EA; Thompson EA; Ballman KV; Anderson SK; Asmann YW; Kalari KR; Eckel-Passow JE; Dueck AC; Tenner KS; Jen J; Fan JB; Geiger XJ; McCullough AE; Chen B; Jenkins RB; Sledge GW; Winer EP; Gralow JR; Reinholz MM J Clin Oncol; 2015 Mar; 33(7):701-8. PubMed ID: 25605861 [TBL] [Abstract][Full Text] [Related]
23. HER2-positive breast cancer, intrinsic subtypes, and tailoring therapy. Ellis MJ J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25139535 [No Abstract] [Full Text] [Related]
24. Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer. Carvajal-Hausdorf DE; Schalper KA; Pusztai L; Psyrri A; Kalogeras KT; Kotoula V; Fountzilas G; Rimm DL J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25991002 [TBL] [Abstract][Full Text] [Related]
25. Systemic therapy for early-stage HER2-positive breast cancers: time for a less-is-more approach? Paplomata E; Nahta R; O'Regan RM Cancer; 2015 Feb; 121(4):517-26. PubMed ID: 25346473 [TBL] [Abstract][Full Text] [Related]
26. [Modern pharmacological therapy of breast cancer]. Láng I; Kahán Z; Hitre E; Dank M; Rubovszky G; Horváth Z; Kásler M Orv Hetil; 2012 Jan; 153(2):56-65. PubMed ID: 22217685 [TBL] [Abstract][Full Text] [Related]
27. NICE guidance on trastuzumab emtansine for HER2-positive advanced breast cancer. Elsada A; Doss S; Robertson J; Adam EJ Lancet Oncol; 2016 Feb; 17(2):143-144. PubMed ID: 26703893 [No Abstract] [Full Text] [Related]
28. Duration of trastuzumab for HER2-positive breast cancer. Montemurro F; Aglietta M Lancet Oncol; 2013 Jul; 14(8):678-9. PubMed ID: 23764182 [No Abstract] [Full Text] [Related]
29. [Is the waiver of chemotherapy for small, node-negative breast cancer justified? ]. Sautter-Bihl ML; Sedlmayer F Strahlenther Onkol; 2015 Jan; 191(1):73-5. PubMed ID: 25729794 [No Abstract] [Full Text] [Related]
31. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Joensuu H; Bono P; Kataja V; Alanko T; Kokko R; Asola R; Utriainen T; Turpeenniemi-Hujanen T; Jyrkkiö S; Möykkynen K; Helle L; Ingalsuo S; Pajunen M; Huusko M; Salminen T; Auvinen P; Leinonen H; Leinonen M; Isola J; Kellokumpu-Lehtinen PL J Clin Oncol; 2009 Dec; 27(34):5685-92. PubMed ID: 19884557 [TBL] [Abstract][Full Text] [Related]
32. Dual HER2 Blockade Helps Prevent Breast Cancer Return. Cancer Discov; 2017 Aug; 7(8):790. PubMed ID: 28588061 [TBL] [Abstract][Full Text] [Related]
33. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer. Perez EA; Ballman KV; Tenner KS; Thompson EA; Badve SS; Bailey H; Baehner FL JAMA Oncol; 2016 Jan; 2(1):56-64. PubMed ID: 26469139 [TBL] [Abstract][Full Text] [Related]